Skip to content
Menu
Search for:
Search Button
Home
About HubLE
Content
HubLE Exchange
HubLE Graphics
HubLE Opinions
HubLE Publications
HubLE Resources
IFMRS
MSK-KP
Other
Fleisch Workshop
Forum
Grants
Menu
Sequential zoledronate therapy prevent rebound bone loss following withdrawal of RANKL inhibition
Albert Kim
December 2021
Albert Kim
Albert Kim
Garvan Institute of Medical Research, Australia
Prev
Previous
Next
Next
Close
Home
Graphics
Publications
Exchange
Opinions
Resources
More
Springer-FOP-Programme
H. Fleisch Workshops
About HubLE
Grants
Webinars
Journals
Forum